USFDA grants EIR to Dr Reddys Labs for Srikakulam plant

Dr Reddy’s Laboratories, a multinational pharmaceutical company, announced that the company has received an establishment inspection report (EIR) for Srikakulam formulations plant.

In an exchange filing made during the market hours on Wednesday, the company informed that it has received an EIR from US Food & Drug Administration (USFDA) in regard to the audit of its Srikakulam formulations plant, Unit 1 (Andhra Pradesh) thereby, indicating closure of the audit.

Adding to this, the company said that the inspection classification of this facility is determined as ‘no action indicated’ (NAI).  

Dr Reddy’s Laboratories has been catering to the needs of pharmaceutical sector for over two decades in India and overseas. Incorporated in 1984, the company has over 190 medications with 60 APIs for drug manufacture, diagnostic kits, critical care and biotechnology product.

At the time of market closing on Wednesday, the stock of Dr Reddy’s Laboratories Ltd was trading at Rs 3,782.40, up by 0.28 per cent against its previous close of Rs 3,772.00. Its 52-week high is Rs 4,099.90 while, its 52-week low is Rs 2,352.00 on BSE.